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ABSTRACT 
Objective: Insomnia complaints are frequent among kidney transplant (kTx) recipients and are 
associated with fatigue, depression, lower quality of life and increased morbidity. However, it is not 
known if subjective insomnia symptoms are associated with objective parameters of sleep architecture. 
Thus, we analyze the association between sleep macrostructure and EEG activity versus insomnia 
symptoms among kTx recipients. 
Methods: Participants (n1 = 100) were selected from prevalent adult transplant recipients (n0 = 1,214) 
followed at a single institution. Insomnia symptoms were assessed by the Athens Insomnia Scale 
(AIS) and standard overnight polysomnography was performed. In a subgroup of patients (n2 = 56) 
sleep microstructure was also analyzed with power spectral analysis. 
Results: In univariable analysis AIS score was not associated with sleep macrostructure parameters 
(sleep latency, total sleep time, slow wave sleep, wake after sleep onset), nor with NREM and REM 
beta or delta activity in sleep microstructure. In multivariable analysis after controlling for covariables 
AIS score was independently associated with the proportion of slow wave sleep (β= 0.263; CI: 0.026 - 
0.500) and REM beta activity (β= 0.323; CI= 0.041-0.606) (p<0.05 for both associations). 
Conclusions: Among kTx recipients the severity of insomnia symptoms is independently associated 
with higher proportion of slow wave sleep and increased beta activity during REM sleep but not with 
other parameters sleep architecture. The results suggest a potential compensatory sleep protective 
mechanism and a sign of REM sleep instability associated with insomnia symptoms among this 
population. 
 
 
Keywords: beta activity, insomnia, kidney transplant recipients, polysomnography, sleep architecture, 
slow wave sleep 
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Introduction 
Several studies suggest that 50–80% of patients with end-stage kidney disease (ESKD) may 
have sleep-related problems, including insomnia [1-4], restless legs syndrome [5-7], periodic limb 
movements in sleep [2, 5-7] and obstructive sleep apnea [8-10]. Successful kidney transplantation 
might alleviate some sleep problems [3, 11], but the prevalence of poor sleep remains remarkably high 
among these patients: 52.5% among kidney transplant (kTx) recipients were poor sleeper in a cohort 
study [12]. We previously showed the percentage of kTx recipients who had at least one insomnia 
complaint was nearly 1.5 times higher compared to the general population [3]. 
Insomnia and poor sleep are frequent complaints in kTx recipients and they are associated 
with fatigue [13], depression [3, 4], pain [4], post-traumatic stress-symptoms [4] and lower quality of 
life [3, 12, 14]. Surprisingly, there is almost a complete lack of information regarding objectively 
measured sleep parameters in kTx recipients. Altough there are a few published articles that report 
polysomnographic assessment of sleep in kTx recipients [15-19] most reports focus on obstructive 
sleep apnea and do not analyze sleep structure in details [16-19]. 
Insomnia disorder is characterized by difficulty falling asleep, difficulty staying asleep or poor 
sleep quality, and it leads to impaired daytime functioning, tiredness, fatigue and sleepiness according 
to the International Classification of Sleep Disorders III and Diagnostic and Statistical Manual of 
Mental Disorders V criteria [20, 21]. These complaints can be of multi-factorial origin among kTx 
recipients. Anxiety, fear of rejection, deteriorating graft function, altered metabolism of sleep-
regulatory mediators, ongoing subclinical inflammation, the presence of other comorbid conditions, 
immunosuppressant (IS) or other medications and hospitalization may all influence a preexisting sleep 
disorder or contribute to de novo emergence of sleep problems [22, 23]. 
Diagnosis of insomnia in CKD is similar to the diagnosis among the general population and it 
is based on clinical interview [23]. The assessment of polysomnography (PSG) is required only when 
a comorbid sleep-disorder is suspected. However, studies using PSG and detailed EEG analysis 
contributed important information about the pathophysiology of insomnia among non-kidney disease 
patients and helped to develop better therapies to improve the subjective symptoms. Patients with 
insomnia disorder often have longer sleep onset latency (SOL) [24, 25], lower total sleep time (TST) 
[24-27], dysregulated sleep homeostasis (less slow wave sleep [SWS] or delta activity) [24, 26, 28, 29] 
or higher wake time after sleep onset (WASO) [24, 25, 27, 30]. Moreover, increased wake-like (beta) 
EEG activity during sleep is also characteristic for patients with insomnia [27, 31, 32]. 
The association of subjective insomnia complaints with objectively assessed sleep architecture 
and EEG activity (microstructure) have not been investigated before among kTx recipients. However, 
gaining insight into the objective structure of sleep behind the subjective symptoms might help to treat 
patients with insomnia more properly among this patients population. Thus, in this study we 
hypothesized that, similarly to patients with insomnia but no kidney disease, insomnia symptoms are 
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associated with altered sleep macro- and microstructure paramateres (longer SOL, shorter TST, less 
SWS and delta activity, higher WASO and beta activity). 
 
Methods 
Sample of patients and data collection 
Data for this analysis are obtained from the ‘‘SLeep disorders Evaluation in Patients after kidney 
Transplantation (SLEPT) study’’ [15, 19, 33-40]. Potentially eligible patients were selected from all 
prevalent adult transplant recipients (‘‘total clinic population’’; n = 1,214) who were regularly 
followed at a single outpatient academic transplant center, the kidney transplant clinic of the Dept. of 
Transplantation and Surgery at Semmelweis University, Budapest, Hungary (Figure 1). 
All patients followed at the clinic on December 31, 2006 were considered for enrollment in the 
Malnutrition and inflammation in transplant (MINIT-HU) study. After applying exclusion criteria 
(transplant received within less than 3 months, presence of active and acute respiratory disorder, acute 
infection or hospitalization within 1 month, surgery within 3 months), 1,198 patients remained (‘‘base 
population’’). From this ‘‘base population’’ we randomly selected and approached 150 patients (‘‘kTx 
study sample’’) using the simple random sampling strategy offered by SPSS 15.0 (IBM Corporation, 
Armonk, New York, USA). 
From these 150 eligible patients (‘‘kTx study sample’’), 50 individuals (33%) refused to participate. 
Consequently, the ‘‘kTx PSG sample’’ who underwent PSG included 100 kTx patients (Figure 1). 
There were no significant differences regarding age and sex between the ’’kTx PSG sample” and those 
who refused to participate (data not shown). The basic characteristics (age, sex, eGFR, hemoglobin, 
serum albumin) of the ‘‘kTx PSG sample’’ were similar to the characteristics of the ‘‘total clinic 
population’’ (data not shown). 
Of all PSG recordings in the ’’kTx PSG sample” 56 had sufficient quality to allow sleep microstruture 
analysis (’’kTx EEG sample”) (Figure 1). There were no significant differences in the baseline 
characteristics between the ’’kTx EEG sample’’ and the 44 participants excluded from the EEG 
analysis, except for significantly lower serum albumin in the ’’kTx EEG sample’’ (Table A.1). 
 
Assessment of insomnia 
The Athens Insomnia Scale (AIS) was used to assess sleep complaints and to identify possible cases of 
insomnia [41, 42]. The AIS consists of eight items, with score range 0–24, with higher scores 
indicating worse sleep. Subjects are asked to grade the severity of the sleep complaints (absent, mild, 
severe, very severe) only if the particular complaint occurred at least three times per week during the 
last month. A cut-off score of 10 has been suggested for epidemiological studies to detect clinically 
significant insomnia [42]. The English version of the AIS had been previously translated to Hungarian 
and validated by our group [43]. 
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Polysomnography (PSG) and sleep staging 
Standard, attended overnight PSG was performed in acoustically isolated and video-monitored sleep 
laboratory equipped with individual suits (SOMNOscreenTM PSG Tele, SOMNOmedics GmBH, 
Germany, CE0494). The following data were recorded: 5 EEG channels (A1, A2, C3, C4, Cz), 
electrooculogram, chin electromyography, tibial electromyography, electrocardiography, airflow, 
thoracic–abdominal movements, pulse oximetry, tracheal sound (snoring) and body position. The 
ground and common reference electrodes were placed at Fpz and Cz, respectively. EEG signals were 
sampled and stored at 128 Hz, low- and high-pass filters were set at 35 Hz and 0.2 Hz, respectively. 
All recordings were performed on weekdays, the timing of “lights off” and “lights on” were mostly set 
around 22:00 and 6:00, respectively. 
Recordings were manually scored by two somnologists (MZM, ASL). Sleep stages were determined in 
30 sec epochs according to Rechtschaffen and Kales [44]. Sleep macroarchitecture was characterized 
by the following variables: sleep onset latency (SOL: time elapsed from “lights off ” to the first 
occurrence of sleep stage 2); total sleep time (TST); wake after sleep onset (WASO: time spent awake 
from sleep onset to “lights on”); sleep efficiency (SE: ratio of total sleep time over the time spent in 
bed); percentages of stages 1, 2, slow wave sleep (SWS: stages 3 and 4 combined) and percentage and 
latency of REM (rapid eye movement) sleep. (With an illustrative aim we included a hypnogram 
[Figure 2.] and a table [Table A.2] summarizing the sleep structure variables measured in the study). 
Respiratory events and periodic leg movements were also scored according to standard criteria [45, 
46]. Apnea was defined as the absence of airflow for more than 10 sec; hypopnea was defined as a 
clearly discernible reduction in airflow for more than 10 sec associated with an arousal and/or 3% 
reduction in oxygen saturation. The apnea-hypopnea index (AHI) was defined as the number of apneas 
and hypopneas per hour of sleep. Periodic limb movements were defined as limb movements with 
duration of 0.5–5 sec; inter-movement interval of 5–90 sec; and separation criteria for limb 
movements occurring in both legs: more than 5 sec between onsets. The periodic limb movement 
index (PLMI) was defined as the number of limb movements per hours during sleep. 
 
Analysis of sleep microstructure 
Sleep microstructure was analysed with power spectral analysis. Prior to power spectral analysis EEG 
artefacts were removed from all EEG channels. For this purpose, EEG segments containing artefacts 
were visually identified and annotated on a 4-second basis by an experienced somnologist using our 
custom-made software (FerciosEEG,  © Ferenc Gombos 2008-2016) [47]. EEG signals were 
subsequently exported, while the annotated segments were excluded from further analysis. Power 
spectral density averaged over the whole night was calculated separately for NREM (stages 2, 3 and 4) 
and REM sleep stages. 
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Artefact-free EEG segments of interest were concatenated and power density was calculated for 
central derivations (C3-Cz, C4-Cz) using Welch's periodogram method as averages over detrended 
Hanning windowed 4-second long epochs with 50% overlap. Frequency-specific absolute spectral 
powers (in µV
2
/Hz) were obtained as the integral of the cubic spline interpolated power values over 
the delta (0.75-4 Hz), theta (4-8 Hz), alpha (8-11 Hz), sigma (11-15 Hz) and beta (15-25 Hz) bands 
divided by the width of the respective band [48-50] (With an illustrative aim we included a spectral 
band picture (Figure 3) of a patient and we summerized the different frequency bands in Table A.2). 
The algorithms were based on the NumPy, SciPy, and Matplotlib libraries for scientific computing 
[51, 52]. 
 
Assessment of depression and comorbidities 
We assessed depressive symptoms with the Hungarian version of the Center for Epidemiologic 
Studies - Depression (CES-D) scale [53]. This was translated and validated by our team using standard 
procedures [54]. This questionnaire contains 20 items that ask participants to grade how frequently 
their complaints occured (rarely, 1-2 days, 3-4 days, 5-7 days) within the last week. The total CES-D 
score was used to describe psychological distress in the sample. 
Comorbidity was assessed by the modified Charlson Comorbidity Index [55] completed by the main 
responsible transplant physician of the participant. Information about medication use was obtained 
from the questionnaires and the medical charts. 
 
Laboratory data 
Laboratory data were extracted from the medical charts, including blood hemoglobin, serum albumin 
and creatinine. Estimated glomerular filtration rate (eGFR) was calculated using the ‘‘4-variable’’ 
CKD-EPI (Chronic Kidney Disease EPIdemiology collaboration) formula [56]. All laboratory data 
was within a month of the sleep study. 
 
Transplantation and donor related data 
Transplantation-related information collected included current medications, transplant and dialysis 
‘‘vintage’’ (i.e., time elapsed since transplantation or time spent on dialysis prior to transplantation), 
history of acute rejection, age and sex of donor and history of delayed graft function. Time elapsed 
since the initiation of the first treatment for ESKD - cumulative ESKD time - was also calculated. 
Standard maintenance IS therapy generally consisted of prednisolone, either cyclosporine A 
microemulsion formulation or tacrolimus, combined with mycophenolate mofetil or azathioprine, 
everolimus or sirolimus. All enrolled kTx recipients were receiving maintenance IS therapy during our 
study. 
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Ethics approval 
The study was approved by the Research Ethics Board of the Semmelweis University (4/2007). Before 
enrollment, patients received detailed verbal and written information about the aims and protocol of 
the study and signed an informed consent. 
 
Statistical analysis 
Statistical analysis was carried out using STATA 13.0 software. Continuous variables were compared 
using Student’s t-test or the Mann-Whitney U test, as appropriate. Categorical variables were analyzed 
using the chi-square test or Fisher's exact test where the observation numbers were low. Correlation 
analysis was performed using Pearson and Spearman rank correlation analysis. 
We analyzed the association between the AIS score and the PSG macrostructure parameters and 
frequency power spectra with multivariable linear regression. The models were built with the sleep 
parameter as dependent variable and the AIS score as independent variable. At first step we included 
the AIS score, age, sex and graft function into Model 1. Additionally the CES-D score and hypnotic 
medication use variables were also included into Model 2. We selected the covariables based on 
theoretical considerations. 
We used transformations (square root – SOL; logarithmic – WASO, power spectra) to achieve normal 
distribution of the variables where it was necessary. In all statistics, two-sided tests were used and 
p<0.05 was considered statistically significant. 
We also performed multivariable analyses of sleep macro- and microstructure versus AIS score 
including additional covariables (AHI, PLMI, Charlson Comorbidity Index, IS medications - data not 
shown) and these variables did not alter the results considerably. Thus, we decided not to include these 
analyses in the present report. 
 
Results 
The demographic and laboratory parameters, comorbid conditions and transplantation related data of 
the ’’kTx PSG sample” are presented in Table 1. Descriptive data of sleep macrostructure parameters 
are presented in Table 2. 
 
Prevalence and severity of insomnia symptoms and their associations with descriptive and sleep 
architecture parameters 
The median (IQR) AIS score was 4 (6) in the ‘’kTx PSG sample’’ (Table 1). Sixteen percent of the 
kTx recipients had high risk of insomnia based on the AIS cut-off score. Seventeen percent of the 
patients were using hypnotic medication. 
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High risk of insomnia was significantly associated with older age, worse kidney function (lower 
estimated glomerular filtration rate [eGFR]), higher number of comorbidities, higher prevalence of 
hypnotic drug use and presence of depression and severity of depressive symptoms (Table 1). These 
associations were analysed and discussed in more details in our previous publication about a larger 
sample of kTx recipients (n = 884) [3]. 
High risk for insomnia was not associated with sleep macrostructure parameters in our sample (Table 
A.3). However, there was a trend towards a negative correlation between the AIS score and SE (r= -
0.178; p= 0.075) (Table 2). No other associations were present between the AIS score and sleep 
macrostructure. 
 
Multivariable analysis of insomnia symptoms versus sleep macrostructure 
We analyzed the selected sleep macrostructure parameters with multivariable linear regression (Table 
3). After controlling for potential confounders (Model 1: age, sex, eGFR and Model 2: age, sex, eGFR, 
CES-D, hypnotic medication use) higher AIS score was significantly associated with higher 
proportion of SWS (β: 0.263; CI: 0.026 - 0.500; p = 0.030). AIS score was not associated with SOL, 
TST or WASO in our sample. (With an explorative aim we also analyzed other sleep parameters in 
multivariable analysis. The results are presented in Table A.4). 
 
Associations of insomnia symptoms and sleep EEG spectra 
In the next step we analyzed the association between AIS score and absolute power spectra (Table 4). 
The AIS score significantly correlated with the REM sigma frequency band (r=0.287; p=0.032) and 
there were trends towards a positive correlation with REM beta (r=0.257; p=0.055) and NREM alpha 
(r=0.244; p=0.070). The AIS score was not associated with power spectra of NREM beta, NREM delta 
or REM delta in the univariable analysis. 
We further analyzed the association of beta and delta power spectra with the AIS score in 
multivariable regression models (Table 5). After adjusting for covariables the AIS score was 
independently associated with higher REM beta (Model 2, β: 0.323; CI: 0.041 - 0.606; p= 0.026). 
Power spectra of NREM beta and delta or REM delta were not associated with AIS score (Table 5). 
(With an explorative aim we also analyzed other frequency bands in multivariable analysis. The results 
are presented in Table A.5.) 
 
Discussion 
This is the first study analyzing detailed sleep architecture and sleep EEG activity associated 
with insomnia symptoms in kTx recipients. Our main finding is that the severity of insomnia 
symptoms is associated with higher amount of SWS and higher beta power during REM sleep. 
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While there is a growing literature about the importance of subjective sleep quality among kTx 
recipients [3, 4, 12, 57], only limited information has been published about the objectively measured 
sleep characteristics in this population. Three prospective studies have reported on the change of sleep 
disordered breathing before and after kidney transplantation [16-18]. These studies yielded 
inconsistent results regarding the improvement of sleep architecture following kidney transplantation 
and reported incomplete data of sleep macrostructure parameters. In the studies which reported SOL 
[16, 17], TST [16], SWS [16-18] and WASO [17] the values were comparable with our findings. 
Additionally, in our previous report we presented data about the severity of depressive symptoms and 
its associations with sleep macrostructure among kTx recipients [15]. 
To gain insight to the sleep characteristics of kTx recipients associated with insomnia 
symptoms first we analyzed sleep macrostructure. Contrary to our expectations, univariable analysis 
did not reveal any significant associations between insomnia symptoms and sleep macrostructure. 
Similarly, SOL, TST and WASO parameters were not associated with symptoms of insomnia in 
multivariable analysis, either. Similar negative findings were also reported in patients with different 
medical conditions comorbid with insomnia [58]. 
Although the previously mentioned parameters of sleep macrostructure were not associated 
with symptoms of insomnia in the current study, contrary to our expectations, higher proportion of 
SWS was associated with higher AIS score in the fully adjusted multivariable model. In the general 
population insomnia has been characterized by lower homeostatic sleep pressure as indicated by less 
SWS [24, 28]. Our results, however, suggest an increased homeostatic sleep pressure associated with 
higher subjective insomnia complaints in kTx patients. This may be either a homeostatic 
rebound/compensation to a less restorative sleep quality experienced on a chronic basis by the patients 
or may be due to intrinsic circadian factors, subclinical inflammation and/or medication. 
Unfortunately, our study design does not enable us to answer this question and further studies are 
needed to determine if an increased proportion of SWS is related to the treatment modality itself or to 
other biological factors related to the kidney disease. 
The so-called ,,paradoxical” increase of SWS was also described in patients with chronic 
fatigue syndrome [59, 60], and this might reflect an attempt to compensate an impaired process 
reflected in ultraslow oscillations [60, 61]. Besides insomnia symptoms, prevalence of fatigue is also 
very high among ESKD and in a study worse subjective sleep quality and higher proportion of stage 2 
sleep (suggesting higher sleep spindling – sleep protection of NREM sleep) was associated with higher 
fatigue score [62]. SWS was not different between the high fatigue versus low fatigue groups, 
however, associations of fatigue with sleep macrostructure parameters were not analysed in 
multivariable analysis. 
Proportion of SWS varies among patients with different stages of CKD and different treatment 
modalities for ESKD. In a large study of more than 1,740 participants with intact or various degree of 
impaired renal function, patients with more advanced CKD tended to have shorter SWS duration after 
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adjustment for age, sex, sleep disordered breathing severity and PLMI [63]. In another work ESKD 
patients treated with ambulatory peritoneal dialysis (APD) had higher proportion of SWS (after 
adjustment for age, sex, race and body mass index) compared to patients with earlier stages of CKD, 
despite that APD patients had worse subjective sleep quality [64]. In two prospective PSG studies the 
proportion of stage 3 sleep was significantly higher after kTx compared to hemodialysis [17, 18], 
however, in one study SWS significantly decreased after kTx [16]. 
In sleep microstructure analysis we could not confirm the association of higher homeostatic 
sleep pressure with insomnia symptoms: NREM delta power was not associated with AIS in our 
sample. However, this might be due to methodological reasons. Here we analysed NREM stages 2,3 
and 4 combined and not SWS separately. Furthermore, we had a 5 channel EEG, however, it is known 
that differences in the power spectrum is not only present at central sites. According to literature 
additional recording for example at frontal sites might rather be informative to capture localized 
association of insomnia symptoms and delta EEG activity [25, 26]. 
In this analysis we also hypothetized that higher wake-like EEG activity (beta) is associated 
with more severe insomnia symptoms among this population. Interestingly, we did not observe an 
association between AIS score and beta frequency band during NREM sleep, however, during REM 
sleep higher beta activity was independently associated with insomnia symptoms after adjustment for 
covariables. Increased beta power during REM sleep was also found in the work of Merica et al. who 
investigated primary insomnia subjects [26]. 
A growing interest has recently been directed to assess the association between ’’REM 
instability” and insomnia [65]. According to this theory microarousals or wake intrusions preceding or 
during REM sleep or relative cortical activation during REM could contribute to altered time-
perception [25, 30, 66]. This, in turn, might worsen the perception of sleep and lead to sleep-
maintenance insomnia complaints. Interestingly, sleep-maintenance insomnia based on the AIS score 
was found to be the most frequent subtype of insomnia among kTx recipients in our previous work [3]. 
Additionally, we found that prolonged REM latency and less REM sleep were associated with the 
severity of insomnia symptoms after controlling for age, sex and graft function in multivariable 
models (data was presented in the Appendix). After additional adjustment for depressive symptoms 
and hypnotic medication use these associations did not remain significant, however, this might be due 
to the relatively small sample size and consequent low statistical power of our study. These results 
together with the association of REM beta activity and insomnia symptoms may indicate higher 
instability of REM sleep among kTx recipients with more severe symptoms. 
Several limitations of this study should be considered when interpreting our results. First of 
all, admittedly, our study sample was quite heterogeneous. Importantly, we did not exclude patients 
with obstructive sleep apnea or periodic limb movement disorder from our analysis. Although in 
studies of insomnia disorder the presence of these sleep disorders usually represent exclusion criteria, 
sleep disorders in kTx recipients in most cases are present simultaneously and excluding those patients 
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would have largely limited enrollment. Furthermore, we wanted to study sleep characteristics in a 
’’real life” clinical patient population on a sample which is representative to the total clinic population. 
For these reasons we decided to select the patients with random sampling and considered obstructive 
sleep apnea or periodic limb movement disorder as potential confounders. (We adjusted the models for 
AHI and PLMI as well and these variables did not alter the results considerably - data was not shown). 
Second, we assessed only a one-night PSG, and for this reason first-night effect might have 
influenced our findings. We did not offer a two-night assessment to enhance acceptability and 
participation in the study. However, the lack of an adaptation night might be one of the reasons why 
the EEG recordings contained substantial amount of artefact. 
Third, patients in this study were taking multiple medications and this might influenced our 
results. We have very little specific knowledge about the effect of IS treatment on EEG spectra and on 
sleep structure. As we mentioned in Methods, we also performed the analysis including IS medications 
as additional covariables in the multivariable models, and they did not alter the results of this report. 
Additionally, 17 % of the patients were taking sleeping pills that can modify EEG activity during sleep 
[67, 68]. For this reason we statistically controlled our models for hypnotic medication use. 
Lastly, we analyzed sleep microstructure only in a subgroup of patients of the “kTx PSG 
sample”. We excluded 44 EEG-s prior to power spectral analysis based on the quality of the EEG 
recordings. This might have introduced selection bias since patients with worse sleep may “produce” 
lower quality sleep recordings (patients excluded from the power spectral analysis did have 
significantly lower SE and shorter TST - data was not shown). However, clinical and socio-
demographic characteristics of excluded subjects were comparable to those remaining in the final 
“kTx EEG sample” (Table A.1), suggesting that the results are still representative to the “total clinic 
population”. 
In summary, in our present report insomnia symptom severity was associated with higher 
proportion of SWS and higher REM beta power in the fully adjusted models. (Other parameters of 
sleep macrostructure and beta and delta power during NREM sleep were not associated with insomnia 
symptoms among kTx recipients.) The observed alterations might be signs of an impaired homeostatic 
sleep regulation and instability of REM sleep associated with insomnia symptoms among this 
population. 
This study is the first analysis that reports sleep architecture in a relatively high number of kTx 
recipients and its association with insomnia symptoms. Most importantly we would like to draw 
attention to the significance of sleep complaints among this population and highlight that insomnia 
symptoms are associated with different alterations in sleep architecture than in the non-kidney disease 
population. Other works are needed to replicate our findings and to explore in more details whether 
higher homeostatic sleep pressure associated with insomnia symptoms is due to some yet undefined 
factors (p.e: fatigue, treatment modality, medications, subclinical inflammation). Future research 
should also investigate whether appropriate interventions to improve sleep (such as sleep hygiene, 
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encouraging siesta, relaxation before sleep or cognitive behavioural therapy for insomnia, CBT-i) 
would change these observed sleep parameters and also improve subjective sleep complaints of kTx 
recipients. 
 
Part of this manuscript has been accepted as poster for the 5th annual conference of the European 
Association of Psychosomatic Medicine. 
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Table A.1 Descriptive data of the kTx EEG sample (n=56) and excluded patients (n=44) 
 
kTx EEG 
sample 
Excluded 
patients 
p 
n 56 44 N/A 
Age (mean±SD) (years) 49±13 53±12 0.068 
Male (%) 62.5 50 0.210 
BMI (mean±SD) (kg/m2) 26±4 27±5 0.165 
eGFR (mean±SD) (ml/min/1.73 m2) 52±18 55±21 0.218 
Serum albumin (mean±SD) (g/L)  40±4 41±3 0.042 
Charlson comorbidity index 
(median;IQR) 
2;1 2;1 0.585 
Prevalence of diabetes (%) 23 14 0.226 
Prevalence of hypertension 
(%) 
89 95 0.460 
Prevalence of insomnia (%) 
(AIS 10 cut-off) 
18 14 0.568 
AIS (median; IQR) 4;8 3.5;4 0.735 
Prevalence of depression (%) 
(CES-D 18 cut-off) 
25 14 0.178 
CES-D (median; IQR) 10;12 9;9 0.260 
Hypnotic drug usage (%) 23 9 0.106 
Antidepressant usage (%) 2 2 1.000 
Transplant vintage (median; 
IQR) (months) 
63;78 77;84.5 0.718 
IS medication (%) 
  steroid 
  cyclosporine 
  azathiophrine 
  sirolimus 
  mycophenolate- mofetil 
  tacrolimus  
  everolim 
 
86 
46 
2 
12.5 
70 
43 
0 
 
84 
39 
9 
11 
73 
50 
2 
 
0.821 
0.435 
0.166 
1.000 
0.736 
0.477 
0.440 
Dialysis vintage (median; IQR) 
(months) 
22;40.5 15.5;23 0.354 
Cumulative ESKD time 
(median; IQR) (months) 
101;95 100.5;91 0.957 
 
AIS: Athens Insomnia Scale; BMI: body mass index; CES-D: Center for Epidemiologic Studies – Depression 
scale; eGFR: estimated glomerular filtrate rate; ESKD: end-stage kidney disease; Immunosuppressant: IS; IQR: 
interquartile range; kTx: kidney transplant; SD: standard deviation  
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Table A.2 Sleep macro- and microstructure parameters 
 
Sleep macrostructure 
parameter 
Definition Abbreviation 
Sleep Onset Latency Time elapsed from “lights off ” to 
the first occurrence of sleep stage 2 
SOL 
Sleep Efficiency Ratio of total sleep time over the 
time spent in bed 
SE 
Total Sleep Time Time spent asleep TST 
Percentage of stage 1 sleep Percentage of stage 1 sleep within 
sleep period time (time from sleep 
onset until final awakening) 
stage 1 
Percentage of stage 2 sleep Proportion of stage 2 sleep within 
sleep period time 
stage 2 
Slow Wave Sleep Proportion of stages 3 and 4 
combined within sleep period time 
SWS 
REM latency Time elapsed from sleep onset to 
the first occurence of REM sleep 
- 
REM percentage Proportion of REM sleep within 
sleep period time 
REM 
Spectral bands Description Frequency 
range 
delta Typical activity during SWS 0.75-4 Hz 
theta Typical activity during stage1 and 
2 sleep and REM sleep 
4-8 Hz 
alpha Typical activity during resting 
wakefulness 
8-11 Hz 
sigma Activity of sleep spindles 11-15 Hz 
beta Typical activity during alert 
wakefulness 
15-25 Hz 
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Table A.3 Polysomnography parameters of the kTx PSG sample and subgroups 
Insomnia (n=16) and Non-Insomnia (n=84) 
 
 kTx PSG 
sample 
Insomnia 
(AIS≥10) 
Non-Insomnia 
(AIS<10) 
p 
SOL (median;IQR) (min) 15;17 16;21 15;18 0.527 
SE (median;IQR) (%) 80;13 75;12 81;13 0.114 
TST (mean±SD) (h) 6±1.3 5.9±1 6.1±1.4 0.282 
Stage 1 (mean±SD) (%) 11±6 10±6 11±7 0.652 
Stage 2 (mean±SD) (%) 43±13 41±13 43±13 0.297 
SWS (mean±SD) (%) 12±8 13±7 12±8 0.253 
REM sleep (mean±SD) (%) 13±6 11±6 13±6 0.126 
REM latency (median;IQR) (min) 145;87 175;121 145;76 0.341 
WASO (median;IQR) (min) 61;47 74;53 59;47 0.175 
AHI (median; IQR) (1/h) 
AHI < 5: without OSA (%) 
AHI ≥ 30: severe OSA (%) 
4;14 
57 
14 
2;6 
69 
6 
4;21 
55 
15 
0.384 
0.411 
0.458 
PLMI (median; IQR) (1/h) 
PLMI < 5: without PLMD (%) 
PLMI ≥ 25: severe PLMD (%) 
6;15 
48 
16 
3;21 
56 
19 
7;15 
46 
15 
0.821 
0.471 
0.717 
 
Insomnia was defined by the cut-off score of the Athens Insomnia Scale (AIS<10: non-insomnia subgroup; 
AIS≥10: insomnia subgroup). AHI: apnea-hypopnea index; AIS: Athens Insomnia Scale; IQR: interquartile 
range; kTx: kidney transplant; REM: rapid eye movement; OSA: obstructive sleep apnea; PLMD: periodic limb 
movement disorder; PLMI: periodic limb movement index; SD: standard deviation; SE: sleep efficiency; SWS: 
slow wave sleep; SOL: sleep onset latency, TST: total sleep time; WASO: wake after sleep onset 
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Table A.4 Associations of sleep macrostructure parameters (dependent variable) and the 
AIS score (independent variable) in multivariable linear regression models (n=100) 
 
Dependent variable β coefficient 95% CI p 
SE (%) Model 1 -0.144 -0.341 -0.052 0.149 
 Model 2 -0.120 -0.350 - 0.111 0.306 
Stage 1 (%) Model 1 -0.062 -0.260 - 0.137 0.538 
 Model 2 -0.082 -0.321 - 0.157 0.498 
Stage 2 (%) Model 1 -0.067 -0.285 - 0.150 0.540 
 Model 2 -0.190 -0.437 - 0.058 0.131 
REM sleep (%) Model 1 -0.217 -0.415 - -0.018 0.033 
 Model 2 -0.117 -0.353 - 0.120 0.328 
REM latency (min) Model 1 0.234 0.027 - 0.442 0.027 
 Model 2 0.235 -0.008 - 0.478 0.057 
Model 1: adjusted for: AIS score, age, sex, eGFR 
Model 2: adjusted for: AIS score, age, sex, eGFR, CES-D score, hypnotic medication use 
We used transformations to achieve normal distribution of the variables when it was necessary (SE: 
cubic, stage 1 sleep and REM latency: square transformation). 
 
AIS: Athens Insomnia Scale; CES-D: Center for Epidemiologic Studies – Depression scale; CI: confidence 
interval; eGFR: estimated glomerular filtrate rate; REM: rapid eye movement; SE: sleep efficiency 
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Table A.5 Associations of sleep EEG spectra (dependent variable) and AIS score 
(independent variable) in multivariable linear regression models (n=56) 
 
Dependent variable β coefficient 95% CI p 
NREM Sigma Model 1 0.177 -0.052 - 0.406 0.127 
 Model 2 0.045 -0.206 - 0.297 0.718 
NREM Alpha Model 1 0.279 0.016 - 0.541 0.038 
 Model 2 0.256 -0.050 - 0.563 0.099 
NREM Theta Model 1 0.117 -0.142 - 0.377 0.367 
 Model 2 0.192 -0.107 - 0.491 0.202 
REM Sigma Model 1 0.345 0.075 - 0.614 0.013 
 Model 2 0.306 -0.005 - 0.616 0.054 
REM Alpha Model 1 0.259 -0.031 - 0.550 0.079 
 Model 2 0.325 -0.012 - 0.663 0.058 
REM Theta Model 1 0.132 -0.160 - 0.423 0.369 
 Model 2 0.255 -0.077 - 0.586 0.129 
 
Model 1: adjusted for: AIS score, age, sex, eGFR 
Model 2: adjusted for: AIS score, age, sex, eGFR, CES-D score, hypnotic medication use 
We used transformations to achieve normal distribution of the variables when it was necessary 
(power spectra: logarithmic transformation). 
 
 
AIS: Athens Insomnia Scale; CES-D: Center for Epidemiologic Studies – Depression scale; CI: confidence 
interval; EEG: electroencephalography; eGFR: estimated glomerular filtrate rate; NREM: non-rapid eye 
movement sleep; REM: rapid eye movement 
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Table 1 Baseline characteristics of the kTx PSG sample and the subgroups Insomnia 
and Non-Insomnia 
 
 
kTx PSG 
sample 
Insomnia 
(AIS≥10) 
Non-
Insomnia 
(AIS<10) 
p 
n (%) 100 (100) 16 (16) 84 (84) N/A 
Age (mean±SD) (years) 51±13 57±12 50±13 0.024 
Male (%) 57 50 58 0.537 
BMI (mean±SD) (kg/m2) 27±5 28±6 27±5 0.167 
eGFR (mean±SD) (ml/min/1.73 m2) 54±19 46±14 55±20 0.042 
Serum albumin (mean±SD) 
(g/L)  
40±3 40±3 40±4 0.412 
Charlson comorbidity index 
(median;IQR) 
2;1 3;2 2;1 0.035 
Prevalence of diabetes (%) 19 31 17 0.179 
Prevalence of hypertension 
(%) 
92 94 92 1.000 
Prevalence of insomnia (%) 
(AIS 10 cut-off) 
16 100 0 N/A 
AIS (median; IQR) 4;6 12;5 3;5 <0.001 
Prevalence of depression 
(%) (CES-D 18 cut-off) 
21 44 16 0.012 
CES-D (median; IQR) 9;11 17;18 9;9 0.035 
Hypnotic drug use (%) 17 37 13 0.017 
Antipdepressant use (%) 2 6 1 0.296 
Transplant vintage (median; 
IQR) (months) 
66;83 72;71 76;85 0.642 
IS medication (%) 
  steroid 
  cyclosporine 
  azathiophrine 
  sirolimus 
  mycophenolate- mofetil 
  tacrolimus  
 
85 
43 
5 
12 
71 
46 
 
81 
56 
6 
0 
75 
38 
 
86 
40 
5 
14 
70 
48 
 
0.704 
0.243 
1.000 
0.205 
1.000 
0.587 
Dialysis vintage (median; IQR) 
(months) 
18;32 26;32 18;30 0.225 
Cumulative ESKD time 
(median; IQR) (months) 
101;91 107;78 101;94 0.694 
 
Insomnia was defined by the cut-off score of the Athens Insomnia Scale (AIS<10: non-insomnia subgroup; 
AIS≥10: insomnia subgroup). AIS: Athens Insomnia Scale; BMI: body mass index; CES-D: Center for 
Epidemiologic Studies – Depression scale; eGFR: estimated glomerular filtrate rate; ESKD: end-stage kidney 
disease; Immunosuppressant: IS; IQR: interquartile range; kTx: kidney transplant; SD: standard deviation  
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Table 2 Polysomnography parameters of the kTx PSG sample and their correlations 
with AIS score 
 
 kTx PSG sample AIS score 
Spearman’s rho 
p 
SOL (median;IQR) (min) 15;17 0.105 0.301 
SE (median;IQR) (%) 80;13 -0.179 0.075 
TST (mean±SD) (h) 6±1.3 -0.127 0.214 
Stage 1 (mean±SD) (%) 11±6 -0.053 0.599 
Stage 2 (mean±SD) (%) 43±13 -0.020 0.844 
SWS (mean±SD) (%) 12±8 0.060 0.557 
REM sleep (mean±SD) (%) 13±6 -0.159 0.115 
REM latency (median;IQR) (min) 145;87 0.142 0.165 
WASO (median;IQR) (min) 61;47 0.088 0.392 
AHI (median; IQR) (1/h) 4;14 -0.026 0.798 
PLMI (median; IQR) (1/h) 6;15 -0.094 0.354 
 
AHI: apnea-hypopnea index; AIS: Athens Insomnia Scale; kTx: kidney transplant; PLMI: periodic limb 
movement index; REM: rapid eye movement; SE: sleep efficiency; SOL: sleep onset latency, SWS: slow wave 
sleep; TST: total sleep time; WASO: wake after sleep onset 
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Table 3 Associations of sleep macrostructure parameters (dependent variable) and AIS 
score (independent variable) in multivariable linear regression models (n=100) 
 
Dependent variable β coefficient 95% CI p 
SOL (min) Model 1 -0.023 -0.179 - 0.225 0.824 
 Model 2 -0.048 -0.285 - 0.188 0.686 
TST (h) Model 1 -0.133 -0.349 - 0.082 0.223 
 Model 2 -0.120 -0.374 - 0.134 0.350 
SWS (%) Model 1 0.113 -0.095 - 0.322 0.282 
 Model 2 0.263 0.026 - 0.500 0.030 
WASO (min) Model 1 0.046 -0.158 - 0.250 0.656 
 Model 2 0.088 -0.158 - 0.335 0.478 
Model 1: adjusted for: AIS score, age, sex, eGFR 
Model 2: adjusted for: AIS score, age, sex, eGFR, CES-D score, hypnotic medication use 
 
AIS: Athens Insomnia Scale; CES-D: Center for Epidemiologic Studies – Depression scale; CI: confidence 
interval; eGFR: estimated glomerular filtrate rate; SOL: sleep onset latency, SWS: slow wave sleep; TST: total 
sleep time; WASO: wake after sleep onset 
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Table 4 Descriptive data of sleep EEG spectra and correlations of AIS score versus sleep 
EEG spectra of the kTx EEG sample (n=56) 
 
 Spectrum absolute 
power µV2/Hz 
(median; IQR) 
AIS score 
Spearman’s rho 
p 
NREM    
Beta 0.30;0.23 0.194 0.152 
Sigma 2.5;3.2 0.142 0.300 
Alpha 3.3;3.4 0.244 0.070 
Theta 5.4;3.5 0.151 0.266 
Delta 51.5;37 0.012 0.931 
REM    
Beta 0.32;0.25 0.257 0.055 
Sigma 0.68;0.58 0.287 0.032 
Alpha 1.4;1.2 0.211 0.118 
Theta 3.2;2.4 0.083 0.545 
Delta 14;9.2 0.197 0.145 
 
AIS: Athens Insomnia Scale; IQR: interquartile range; kTx: kidney transplant; NREM: non-rapid eye movement 
sleep; EEG: electroencephalography; REM: rapid eye movement sleep 
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Table 5 Associations of the sleep EEG spectra (dependent variable) and the AIS score 
(independent variable) in multivariable linear regression models (n=56) 
 
Dependent variable β coefficient 95% CI p 
NREM Beta Model 1 0.238 -0.017 - 0.494 0.067 
 Model 2 0.160 -0.132 - 0.451 0.276 
NREM Delta Model 1 0.079 -0.156 - 0.314 0.503 
 Model 2 0.194 -0.064 - 0.452 0.138 
REM Beta Model 1 0.452 0.200 - 0.705 0.001 
 Model 2 0.323 0.041 - 0.606 0.026 
REM Delta Model 1 0.144 -0.145 - 0.433 0.322 
 Model 2 0.273 -0.050 - 0.595 0.096 
 
Model 1: adjusted for: AIS score, age, sex, eGFR 
Model 2: adjusted for: AIS score, age, sex, eGFR, CES-D score, hypnotic medication use 
 
AIS: Athens Insomnia Scale; CES-D: Center for Epidemiologic Studies – Depression scale; CI: confidence 
interval; EEG: electroencephalography; eGFR: estimated glomerular filtrate rate; NREM: non-rapid eye 
movement sleep; REM: rapid eye movement 
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Figure 1. Selection of patients 
 
 
 
Figure legend: 
EEG: electroencephalography; kTx: kidney transplant; PSG: polysomnography 
 
  
Total clinic population of kTx patients 
followed at the outpatients clinic 
(n=1214) 
Base population 
(n=1198) 
kTx study sample 
(n=150) 
kTx PSG sample 
(n=100) 
Not in the 
random 
sample 
(n=1048) 
Excluded 
(n=16) 
Refused to 
participate 
(n=50) 
Exclusion 
criteria 
Random 
selection 
Informed 
consent 
kTx EEG sample 
(n=56) 
Low EEG 
quality 
(n=44) 
EEG evaluation 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
27 
 
Figure 2. Hypnogram of a study participant to illustrate stages of sleep during the sleep study 
 
 
 
Figure legend: 
Time is plotted on the abscissa and stages on the ordinate, stages are abbreviated as follows: W: stage 
wake; R: stage REM; 1: stage 1; 2: stage 2; 3: stage 3; 4: stage 4. 
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Figure 3. Spectrogram of a patient during NREM and REM sleep 
 
 
 
Figure legend: 
The power spectrum is a function that represents the strength (power) of EEG oscillations at each 
studied frequency bin. 
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Highlights: 
First polysomnography study analyzing sleep architecture associated with insomnia symptoms among 
kidney transplant recipients. 
Insomnia symptoms were independently associated with higher proportion of slow wave sleep. 
Insomnia symptoms were independently associated with increased beta activity during REM sleep. 
The results suggests a compensatory sleep protective mechanism and a sign of REM sleep instability 
associated with insomnia symptoms among kidney transplant recipients. 
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